40 results
424B3
PRDS
Pardes Biosciences Inc
7 Nov 22
Prospectus supplement
4:14pm
their ability to hire and retain key leadership and other personnel, prevent new or existing product candidates from being developed or commercialized
424B3
PRDS
Pardes Biosciences Inc
15 Aug 22
Prospectus supplement
5:41pm
and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new or existing product
424B3
v79lgsegami3 yww0
10 May 22
Prospectus supplement
4:35pm
8-K
EX-99.1
r552jdbw
10 May 22
Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:08pm
DEF 14A
4r64q5e3 fbw
26 Apr 22
Definitive proxy
6:07am
424B3
0thxtzxj
1 Apr 22
Prospectus supplement
4:01pm
POS AM
tzrhhi
30 Mar 22
Prospectus update (post-effective amendment)
7:32am
10-K
9bn37l 03pbx2upudshq
29 Mar 22
Annual report
5:29pm
8-K
EX-99.1
e9dyt0yhjl 5iqrztl
29 Mar 22
Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
7w3o92w
9 Mar 22
Regulation FD Disclosure
11:12am
424B3
pf635lc2fm49 taxl
2 Mar 22
Prospectus supplement
4:23pm
8-K
EX-99.1
sjnlq4m
2 Mar 22
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
4:16pm
8-K
EX-99.2
cpt 99syvjxu
14 Feb 22
Regulation FD Disclosure
7:26am
424B3
vodfkt00dt
1 Feb 22
Prospectus supplement
5:03pm